Design, synthesis, and biological evaluation of novel FXR agonists based on auraptene

Bioorg Chem. 2021 Oct:115:105198. doi: 10.1016/j.bioorg.2021.105198. Epub 2021 Jul 21.

Abstract

Farnesoid X receptor (FXR) has been considered as an attractive target for metabolic disorder and liver injury, while many current FXR agonists suffer from undesirable side effects, such as pruritus. Therefore, it is urgent to develop new structure types different from current FXR agonists. In this study, a series of structural optimizations were introduced to displace the unstable coumarin and geraniol scaffolds of auraptene (AUR), a novel and safe FXR agonist. All of these efforts led to the identification of compound 14, a potent FXR agonist with nearly fourfold higher activity than AUR. Molecular modeling study suggested that compound 14 fitted well with binding pocket, and formed the key ionic bond with His291 and Arg328. In acetaminophen-induced acute liver injury model, compound 14 exerts better therapeutic effect than that of AUR, which highlighting its pharmacological potential in the treatment of drug-induced liver injury.

Keywords: FXR; N-acetyl-p-aminophenol.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Coumarins / chemical synthesis
  • Coumarins / chemistry
  • Coumarins / pharmacology*
  • Dose-Response Relationship, Drug
  • Drug Design*
  • Humans
  • Molecular Structure
  • Receptors, Cytoplasmic and Nuclear / agonists*
  • Structure-Activity Relationship

Substances

  • Coumarins
  • Receptors, Cytoplasmic and Nuclear
  • farnesoid X-activated receptor
  • aurapten